BIOIBERICA
IMPROMUNE BOTTLE 40 APPETIZING TABLETS
IMPROMUNE BOTTLE 40 APPETIZING TABLETS
Secure payment
Discreet and sanitized package
Fast and safe shipping
Description
Description
IMPROPER
Complementary food for dogs and cats to support a normal immune system.
Ingredients
Each tablet contains: nucleotides (Nucleoforce) 585 mg, Lentinus edodes (AHCC, Shiitake mushroom) 315 mg, flavouring by-product (chicken) 72 mg, magnesium stearate 13 mg.
Analytical components: crude protein 45.6%, crude fibre 25.8%, crude ash 5.1%, crude fat 1.7%.
How to use
Impromune should be administered to dogs and cats according to the following schedule:
| Animal weight | Tablets per day |
| <10 kg 10-25 kg >26 kg |
½ 1 2 |
Warnings
This package contains a non-toxic dehydrating agent for product preservation. For veterinary use only.
Conservation
Store in a cool, dry place.
Format
40 palatable tablets.
Net weight: 70 g.
BIOIBERICA
IMPROMUNE BOTTLE 40 APPETIZING TABLETS
IMPROMUNE BOTTLE 40 APPETIZING TABLETS
Couldn't load pickup availability
Product images are purely indicative and may not be fully representative of the packaging and product features, as they may vary in color, size, or content. Any decorations, gift wrapping, and items included in the images for product presentation purposes will not be shipped with orders. Product names, ingredients, and percentages indicated in the descriptions are purely indicative and may be subject to change or updates by the manufacturers. Due to the impossibility of updating these updates in real time, the photos and technical information of the products listed on farmaInnovation.it may differ from those shown on the label or otherwise disclosed by the manufacturers. The only identifying element is the MINSAN (Ministry of Health) code. Farmacia Barni, farmainnovation.it , does not guarantee the accuracy and timeliness of the information published and declines all responsibility for any errors, omissions, or failure to update it. farmainnovation.it assumes no responsibility for damages of any kind that may arise from accessing the published information.
